Carol Ashe

Chief Business Officer, New York Genome Center

Carol Ashe is a seasoned executive with over 25 years of experience in pharmaceutical and consumer healthcare business development, corporate development and venture capital.  Carol currently serves as the Chief Business Officer for the New York Genome Center (a consortium of renowned academic, medical and industry leaders focused on translating genomic research into clinical solutions for diseases) and is responsible for identifying and executing on revenue generating business development opportunities. Previously, in addition to providing business development consulting services to early, late and commercial stage biotechnology and pharmaceutical companies, Carol was Vice President of Corporate Development for Endo’s three pharmaceutical business units (Branded, Generics and Implant Drug Delivery Technology).  Prior to Endo, Carol was a Partner at SR One
(GlaxoSmithKline’s Corporate Venture Capital fund) where she helped source and evaluate opportunities, and facilitated SR One’s investments in both Alios (acquired by J&J for $1.75 billion) and Aileron, sitting as a Board Observer for both companies. Before she joined SR One, Carol was the Vice President, Legal Operations Corporate Functions – US at GSK where she led legal support for corporate staff functions in the US including mergers, acquisitions and equity investments such as GSK’s acquisition of Reliant Pharmaceuticals ($1.65 billion private company acquisition), Sirtris Pharmaceuticals ($720 million private company acquisition) and Genelabs ($57 million public company acquisition).

Prior to her corporate legal role, Carol was the Vice President & Associate General Counsel, Head – BD Legal Transactions Team at GSK for many years and led a large, internationally based team that provided business development transactional legal support for GSK’s Pharmaceuticals and Consumer Healthcare businesses on both a US and global basis. Carol is a registered patent attorney with the USPTO. She holds a J.D. from the Villanova University School of Law and a B.S. in Biology from the Pennsylvania State University.